A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma

Vivien Bramwell; Martin Blackstein; Karl Belanger; Shail Verma; Sandra Beare; Elizabeth Eisenhauer

doi:10.1080/13577149878136

Sarcoma (Jan 1998)

A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma

Vivien Bramwell,
Martin Blackstein,
Karl Belanger,
Shail Verma,
Sandra Beare,
Elizabeth Eisenhauer

Affiliations

Vivien Bramwell: London Regional Cancer Centre, Ontario, Canada
Martin Blackstein: Mt Sinai Hospital, Toronto, Canada
Karl Belanger: Hopital Notre-Dame, Montreal, Canada
Shail Verma: Ottawa Regional Cancer Centre, Ontario, Canada
Sandra Beare: National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG), Ontario, Kingston, Canada
Elizabeth Eisenhauer: National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG), Ontario, Kingston, Canada

DOI: https://doi.org/10.1080/13577149878136
Journal volume & issue: Vol. 2, no. 1
pp. 29 – 33

Abstract

Read online

Purpose: To determine the efficacy and toxicity of docetaxel as first-line chemotherapy in adult patients with locally advanced and/or metastatic soft tissue sarcoma (STS).

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/5805

About the journal